The most concrete date in cancer-drug investing right now is November 14, 2026. That is when the US Food and Drug Administration is due to act on Summit Therapeutics' application for ivonescimab, a bispecific drug that attacks cancer through two targets at once. The application rests on results from the HARMONi trial.1 Around that date sits a wider shift, in which drug developers and big pharma partners are putting money behind newer kinds of cancer medicine rather than familiar ones: bispecifics, personalized mRNA vaccines and protein degraders.2
This piece separates what is checked from what is hoped for. The checked part comes from Summit's own regulatory filings. The hoped-for part, especially around artificial intelligence, mostly comes from interviews and forecasts.
What Summit's filings show: a big bet with no sales yet
Summit reported zero revenue in both 2023 and 2024.3 Over the same years its costs climbed steeply. Net loss was $614.9 million in 2023, fell to $221.3 million in 2024, then reached $1.08 billion in 2025.3 The 2025 loss is about 4.9 times the 2024 figure. Loss per share went from -$0.99 to -$0.31 to -$1.44 over the three years.3
Cash actually spent running the business tells a similar story, though the numbers are smaller than the headline loss. Operating cash flow was -$76.8 million in 2023, -$142.1 million in 2024 and -$322.9 million in 2025, so the cash burn more than doubled in the latest year.3 The filings we hold do not explain why the net loss is so much larger than the cash burn, so we do not guess at the reason.
The cash balance has swung widely. It was $225.3 million at the end of 2025 and $106.5 million in the first quarter of 2026. By the second quarter of 2026 it had risen to $419.4 million, nearly four times the previous quarter.3 The data we hold shows the rise but not its cause, so we do not attribute it to any specific financing. Capital spending on equipment and facilities was small, at $657,000 in 2025, up from $139,000 the year before.3
For an ordinary investor the lesson is plain. Summit is a company whose value depends almost entirely on a regulatory decision, not on sales. Our dossier contains no index weightings, so we cannot say whether a typical fund holds it.
Regulators are saying yes to some of the newer approaches
On October 9, 2026, the FDA approved Tecentriq, and its Hybreza version, combined with chemotherapy drugs for stage III colon cancer in patients whose tumors have a specific genetic feature called dMMR. The approval rests on the Phase III ATOMIC study and is Tecentriq's twelfth US indication.4 Our research narrative treats this as evidence that regulators are rewarding the shift in approach.2
In Europe, an expert committee of the European Medicines Agency recommended Gilead's Trodelvy plus Keytruda as a first treatment for metastatic triple-negative breast cancer in patients whose tumors carry the PD-L1 marker. That was on July 24, 2026. Gilead says the trial showed a highly statistically significant reduction in the risk of disease progression or death.5 This is a recommendation, not a final authorization. As oncologist Evandro de Azambuja put it, "People with metastatic triple-negative breast cancer need effective treatment options as early as possible in the course of their disease, particularly when their tumors express PD-L1."5
In a smaller case, Kyowa Kirin's final MINT study in 109 patients across 18 German centres found a median time to next treatment of 14.9 months with mogamulizumab in two rare blood cancers. The best overall response rate was 62.4% and median progression-free survival was 20.2 months.6 These are real-world results from routine care, not a controlled trial.
Vaccines and the talent shift
Moderna and Merck plan to present detailed results for their personalized mRNA vaccine, intismeran, at the ESMO cancer conference on October 24. They also plan to talk to regulators about possible filings.7 Nothing has been filed yet, and the results themselves are not in our dossier, so the outcome remains open.
In the same field, Everest Medicines hired two former Moderna cancer-vaccine scientists on October 9, 2026. Brandon Coder becomes Vice President, Translational Sciences & Discovery, and Lakshmi Srinivasan becomes Senior Vice President, Head of Translational Medicine.8 Hiring is a signal of intent, not proof that a vaccine works.
Selling, not just researching
Novocure, which sells a device-based cancer therapy, reported quarterly net revenue of $184 million for the quarter ended June 30, 2026. That is up 16% on a year earlier, with global active patient numbers up 18%.9 CEO Frank Leonard said: "This was our strongest quarter to date, with record net revenues and active patients on therapy."9 It is a company statement, but the revenue and patient figures come from the same results release.
Money is also moving into the businesses that deliver cancer care. Our research narrative records McKesson and the private-equity firm CD&R acquiring Option Care Health, after the earlier Precision Medicine Group deal.2 Our dossier does not include the terms, so we do not report a price.
The AI claims: hope, not yet evidence
Much of the long-term optimism rests on AI-designed medicines, and here the sourcing is thinnest. The main source is an MIT Technology Review piece quoting Puja Sapra on AstraZeneca's approach. Our system measured that source's reliability at 0% of 11 checked claims holding up, a score that reflects how we could check it, not a verdict on the speaker's honesty. We treat everything in it as opinion and forecast.10
What it says is ambitious. Sapra describes a "lab of the future": "Where a self-driving car uses sensors and models to navigate its environment, this system uses AI to make predictions, robotic systems to execute experiments, and instruments to generate data."10 She also names the company's edge: "Data is our differentiator."10
She is also frank about the limits. "One of the hardest problems in de novo design is predicting whether a computationally generated molecule will be safe in the human body."10 And she expects people to stay in charge: "With more autonomous systems, human oversight remains at the heart of this approach—ensuring explainable and ethical AI for the benefit of patients."10 Her description of what the data could bring is conditional as well: automated systems "have the potential to help accelerate early drug development timelines significantly."10
Nothing in our dossier shows an AI-designed cancer drug approved or even in late-stage testing. Every statement above is about what may happen.
A note on source quality
The company press releases we rely on for Tecentriq, Trodelvy, Novocure and MINT came through a feed whose claims held up 56% of the time across 4,960 checks.4,5,6,9 That figure is a warning to read releases as claims by the companies, not as independent findings. The Summit financial figures are different. They are checked against the company's regulatory filings.3
What to watch
- October 24: detailed intismeran data at ESMO, and whether Moderna and Merck say anything concrete about filing.7
- November 14: the FDA's decision date on ivonescimab. For a company with no revenue and a $1.08 billion annual loss, the outcome is the main event.1,3
- Summit's next cash figures: whether the jump to $419.4 million holds against a cash burn that has been rising.3
- Europe's final decision on Trodelvy plus Keytruda following the committee's positive opinion.5
